- Home
- SPAI vs CYPH Comparison
SPAI vs CYPH Comparison
Compare SPAI & CYPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SPAI | CYPH |
|---|---|---|
| Founded | 2021 | 2011 |
| Country | United States | United States |
| Employees | 15 | 6 |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.5M | 73.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SPAI | CYPH |
|---|---|---|
| Price | $3.84 | $0.71 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | 121.8K | ★ 2.2M |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1,060.58 | N/A |
| Revenue Next Year | $162.46 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.86 | $0.49 |
| 52 Week High | $9.16 | $3.70 |
Technical Indicators
Market Signals| Indicator | SPAI | CYPH |
|---|---|---|
| Relative Strength Index (RSI) | 38.77 | 47.90 |
| Support Level | $3.45 | $0.58 |
| Resistance Level | $4.74 | $0.80 |
| Average True Range (ATR) | 0.26 | 0.06 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 24.05 | 66.45 |
Price Performance
Historical ComparisonAbout SPAI Safe Pro Group Inc.
Safe Pro Group Inc operates to acquire security and protection products. The company operated in three reportable business segments, which consisted of the business of Safe-Pro USA, the business of Airborne Response, and the business of Safe Pro AI. The majority of revenue is from Safe-Pro USA.
About CYPH Cypherpunk Technologies Inc.
Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.